Health, Fitness & Food

In this article MRNA Follow your favorite stocksCREATE FREE ACCOUNT The Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024.  Adam Glanzman | Bloomberg | Getty Images Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company
0 Comments
In this article WBA Follow your favorite stocksCREATE FREE ACCOUNT People walk by a Walgreens on Nov. 3, 2024 in Brookline, Massachusetts. Danielle DeVries | CNBC Walgreens on Friday reported fiscal first-quarter earnings and revenue that topped expectations, as it shutters stores and cuts other costs to steer itself out of a rough spot. Here’s
0 Comments
In this article LLY NOVO.B-DK CI Follow your favorite stocksCREATE FREE ACCOUNT Packages of weight loss drugs Wegovy, Ozempic and Mounjaro. Picture Alliance | Getty Images A few years ago, when Virta Health founder and CEO Sami Inkinen approached employers about leveraging the company’s nutrition-oriented digital diabetes program for obesity-related weight loss, most companies weren’t
0 Comments
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, August 29, 2020. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The U.S. Food and
0 Comments
In this article NOVO.B-DK LLY Follow your favorite stocksCREATE FREE ACCOUNT An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Medicare drug plans can now cover Eli Lilly‘s blockbuster obesity drug Zepbound for obstructive sleep apnea, CNBC confirmed on Wednesday. 
0 Comments
Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that. Year-to-date performance: down 0.1% Forward price-to-earnings multiple: 27.8 versus a five-year average of 28.8 Our rating: Buy-equivalent 1 Our price target: $305 a
0 Comments
In this article LLY Follow your favorite stocksCREATE FREE ACCOUNT An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters The roughly $1,000 monthly price tag of Eli Lilly‘s weight loss drug Zepbound put the blockbuster treatment out of reach for
0 Comments
In this article LLY Follow your favorite stocksCREATE FREE ACCOUNT An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024.  Shelby Knowles | Bloomberg | Getty Images The Food and Drug Administration on Friday approved Eli Lilly‘s blockbuster weight loss drug Zepbound for
0 Comments
Suki CEO Punit Singh Soni. Courtesy: Suki Health-care artificial intelligence startup Suki on Wednesday announced a new collaboration with Google Cloud as part of its push to expand beyond clinical documentation.  Through the partnership, Suki is building patient summary and Q&A features using Google Cloud’s Vertex AI platform, which allows developers to train, tune and
0 Comments
A person holds a sign while standing on the roadside near the McDonald’s restaurant where a suspect in the killing of the CEO of UnitedHealthcare, Brian Thompson, identified as Luigi Mangione, 26, was arrested, in Altoona, Pennsylvania, U.S. December 9, 2024.  Matthew Hatcher | Reuters The deadly, targeted shooting of UnitedHealthcare CEO Brian Thompson has
0 Comments